Pioneering Futures: JMM and éthica Capital Unveil Top Small Cap Innovators in Sydney's Exclusive Investment Event
SYDNEY – 13 May 2024: Jane Morgan Management partnered with éthica capital to host an exclusive event in Sydney on May 2nd, 2024, showcasing some of ASX's most promising Small Caps.
The JMM & éthica capital Innovation & Investment Lunch provides a platform for ASX-listed companies to present their stories directly to brokers, fund managers, and high net worth investors in a dynamic setting.
In the past, JMM hosted the JMM Sydney Investor Lunch, featuring presentations from some of ASX's most promising Small Caps.
The event took place at the Opera House, Sydney, in September 2023, providing a platform for representatives from various companies including the likes of Queensland Pacific Metals (ASX:QPM), Arizona Lithium (ASX:AZL), and Latin Resources Limited (ASX:LRS).
MedTech in Australia
Majority of companies presenting belong to the MedTech industry.
AusBio Tech states that “Australia is positioned to emerge as a global frontrunner in medical technology, backed by robust expertise in fields like genomic medicine, digital healthcare, and precision medicine”.
The Australian MedTech market was estimated to be worth around USD $8.7 billion in 2023 (MarkWide Research).
Statista predicts a Compound Annual Growth Rate (CAGR) of 6.16% between 2024 and 2028, reaching a market volume of USD $10.11 billion by 2028 (Statista Market Forecast)
Aerospace and Defence in Australia
Presenters like Elsight (ASX:ELS) belong to the Drones communication industry.
The commercial drone industry in Australia is on the verge of a significant turning point. Projections suggest a remarkable growth trajectory over the next two decades, with an average annual increase of 20% in drone flights.
The commercial drone market, valued at USD 772 million in 2023, is forecasted to expand at a CAGR of 15.3% from 2024 to 2030. This robust growth is attributed to the rising adoption of drones across diverse industries including agriculture, delivery and logistics, energy, among others.
As drones find increasing applications in various sectors, their market is witnessing rapid expansion, fuelling optimism for sustained growth in the foreseeable future.
Tech in Australia
As per a report from GlobalData, Australia's Information and Communications Technology (ICT) market exceeded $78 billion in 2022.
The report forecasts a double-digit growth trajectory, with a projected Compound Annual Growth Rate (CAGR) of over 13% for the Australian ICT market from 2022 to 2027. This growth trajectory indicates a potential market value exceeding $146 billion by 2027.
Report also states that “Growth is expected to be fueled by the adoption of emerging technologies like artificial intelligence (AI), cloud computing, cybersecurity, and the Internet of Things (IoT)”
The Australian government is actively supporting the tech sector through various initiatives, fostering an environment conducive to growth with inclusion of a growing pool of skilled IT professionals, making it an attractive location for tech companies to set up operations.
Founder and Director of JMM, Jane Morgan commented: “We are thrilled to have partnered with éthica Capital for this year's Innovation & Investment Insights Lunch, where we showcased some of the most promising small cap companies on the ASX. This event not only highlights the vibrant potential within Australia's smaller enterprises but also strengthens the bridge between innovative leaders and astute investors. Our commitment remains firm in bringing forward-thinking solutions and groundbreaking opportunities to the forefront of Australia's financial landscape.”
About the speakers
BlinkLab Limited (ASX:BB1)
Brian Leedman, Chairman
BlinkLab (ASX:BB1), headquartered in Australia, is dedicated to revolutionising mental healthcare with an AI-driven smartphone application, born from ground-breaking research at Princeton University.
Their pioneering methodology harnesses the capabilities of smartphones, AI, and machine learning to administer tailored screening tests, tailored for children as young as 18 months old.
Upon regulatory approval, this state-of-the-art digital innovation stands ready to captivate investors and leading pharmaceutical firms, keen on embracing game-changing healthcare solutions.
BlinkLab Limited (ASX:BB1) | JMM & éthica Capital Innovation & Investment Insights | May 2024
Cynata Therapeutics Limited (ASX:CYP)
Dr Kilian Kelly, CEO and Managing Director
Cynata Therapeutics Limited (ASX:CYP) is pioneering the development of Cymerus™️, an exclusive stem cell platform designed for the efficient production of high-quality mesenchymal stem cell (MSC)-based therapies.
Their primary candidate, CYP-001, displays promising results in addressing steroid-resistant acute graft-versus-host disease (GvHD), with ongoing clinical trials targeting GvHD, osteoarthritis, and diabetic foot ulcers (DFU).
The Cymerus technology stands out due to its ability to generate consistent MSCs from a single cell bank, offering significant advantages over traditional methods. These advancements hold potential for addressing various diseases, as evidenced by preclinical models.
Cynata Therapeutics (ASX:CYP) | JMM & éthica Capital Innovation & Investment Insights | May 2024
Imugene (ASX:IMU)
Leslie Chong, CEO & Managing Director
Imugene (ASX:IMU) stands as a clinical-stage immuno-oncology enterprise, dedicated to pioneering a diverse array of innovative immunotherapies. These therapies are designed to stimulate the immune systems of cancer patients, aiming to combat and eliminate tumours effectively.
Leveraging their distinctive platform technologies, they endeavour to empower the body's immune response against tumours, with the potential to deliver outcomes comparable to, or surpassing, those of synthetically manufactured monoclonal antibodies and other immunotherapeutic approaches.
Imugene (ASX:IMU) | JMM & éthica Capital Innovation & Investment Insights | May 2024
Bcal Diagnostics Limited (ASX:BDX)
Jayne Shaw, Executive Chair
Bcal Diasgnostics (ASX:BDX) is a leading Australian firm dedicated to the timely and precise detection of breast cancer. At the forefront of innovation, BCAL has engineered a non-invasive blood test demonstrating encouraging efficacy in breast cancer diagnosis, independent of breast tissue density.
This ground-breaking test is crafted to supplement current imaging methodologies, aspiring to evolve into a primary screening and monitoring instrument for women across the globe.
With over two million new cases of breast cancer diagnosed worldwide annually, BCAL stands prepared to make substantial strides in improving patient outcomes.
Bcal Diagnostics (ASX:BDX) | JMM & éthica Capital Innovation & Investment Insights | May 2024
Elsight (ASX:ELS)
Yoav Amitai, CEO
Elsight (ASX:ELS) is dedicated to providing "Connection Confidence" through its proprietary bonding technology, which seamlessly integrates software and hardware components to deliver dependable, secure, high-bandwidth, real-time connectivity.
This innovative solution ensures connectivity even in the most demanding environments, catering to stationary, portable, or actively mobile situational requirements.
Established in 2009, Elsight has rapidly expanded its reach, offering robust and secure connectivity solutions to drone manufacturers, operators, and integrators worldwide.
Elsight (ASX:ELS) | JMM & éthica Capital Innovation & Investment Insights | May 2024
4DS (ASX:4DS)
Howard Digby, Non-Executive Director
4DS Memory Limited (ASX: 4DS), situated in Silicon Valley, is a semiconductor technology pioneer specialising in delivering high-bandwidth, high-endurance, non-volatile memory solutions for cutting-edge CMOS process nodes.
Its technology, Interface Switching ReRam, offers adjustable persistence and low energy consumption per bit, making it ideal for today's most demanding compute-intensive and AI processor applications.
4DS Memory (ASX:4DS) | JMM & éthica Capital Innovation & Investment Insights | May 2024
Whitehawk (ASX:WHK)
Terry Roberts Founder, President, CEO
WhiteHawk (ASX:WHK) has pioneered the development of the first cloud-based, AI/ML-driven cyber risk monitoring, prioritisation, and mitigation platform, revolutionising access for companies and organisations to manage their digital age risks and those of their suppliers/vendors efficiently and affordably.
Offering 100% automated product lines, including one-time or annual subscriptions for Cyber Risk Programs (enterprise-level) or Cyber Risk, as well as virtual Cyber Consults tailored to client needs, WhiteHawk ensures continuous cybersecurity readiness.
WhiteHawk (ASX:WHK) | JMM & éthica Capital Innovation & Investment Insights | May 2024
Praemium (ASX:PPS)
David Coulter, CFO
Praemium (ASX: PPS) stands as Australia's premier investment platform, serving both emerging and established segments of the High Net Worth (HNW) market.
Trusted by some of the world's foremost private wealth managers, institutions, and intermediaries, Praemium's technology fuels client portfolios for a notable portion of the Barron's Top 100 Advisers 2023, representing 40% of this esteemed list.
Praemium (ASX:PPS) | JMM & éthica Capital Innovation & Investment Insights | May 2024
To register your interest to join the next JMM Investor Insights event click the link below:
https://janemorganmanagement.com.au/register/
About us:
Jane Morgan Management (JMM) is a boutique Investor Relations & Media Communications consultancy group, and for over 16 years, has been providing strategic investor and media relations services to ASX listed companies, across a diverse range of industries including mining and resources, food and beverage, technology, blockchain, SaaS, cryptocurrency, fintech, biotech and consumer goods.
Contact details:
Jane Morgan
jm@janemorganmanagement.com.au
